Armata Pharmaceuticals Inc. is a leading biotechnology company committed to transforming the treatment of bacterial diseases. With a strong corporate philosophy centered around innovation, dedication, and patient-centric solutions, Armata strives to deliver life-saving therapies for high unmet medical needs. The company values transparency, scientific excellence, and collaboration to address the global healthcare challenges posed by antibiotic-resistant infections. Through its extensive research and development efforts, Armata Pharmaceuticals Inc. aims to revolutionize the field of antimicrobial therapeutics, providing hope for patients and healthcare professionals worldwide.

Armata Pharmaceuticals Inc primarily operates in the United States.

Armata Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed a merger with C3J Therapeutics, Inc. in 2019, expanding its research and development capabilities. In the same year, Armata Pharmaceuticals initiated a Phase 1 clinical study of its lead product candidate, AP-SA01, for the treatment of Staphylococcus aureus infections. In 2020, the company received FDA Fast Track designation for AP-PA02, another candidate for the treatment of Pseudomonas aeruginosa infections. These milestones highlight Armata Pharmaceuticals' advancements in developing innovative therapies to address serious and drug-resistant bacterial infections, solidifying its position as a leader in the field.

Armata Pharmaceuticals Inc is a biotechnology company that specializes in developing phage-based therapeutics to combat antibiotic-resistant infections. Founded in 2018, Armata Pharmaceuticals emerged from the merger of two phage therapy companies, AmpliPhi Biosciences Corporation and C3J Therapeutics Inc. By leveraging its proprietary bacteriophage platform, Armata aims to address the growing global threat of antibiotic resistance. The company's rigorous research and development activities focus on creating novel phage-based products to target multidrug-resistant bacteria. With a commitment to transforming the treatment landscape, Armata Pharmaceuticals Inc is dedicated to providing innovative solutions for patients suffering from serious and life-threatening infections.

The main competitors of Armata Pharmaceuticals Inc in the market are companies such as ContraFect Corporation, AmpliPhi Biosciences Corporation, and AvidBiotics Corporation.

Armata Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Armata Pharmaceuticals Inc. is centered around developing and commercializing bacteriophage-based therapies to treat antibiotic-resistant infections. As a biotechnology company, Armata focuses on leveraging the potential of phage technology to address the growing global health threat posed by multidrug-resistant bacteria. By targeting specific bacteria strains, their therapeutic platforms aim to provide effective and innovative solutions for life-threatening infections. Armata Pharmaceuticals Inc. employs a research-driven approach and strategic partnerships to develop novel therapies and ultimately improve patient outcomes in the fight against antibiotic resistance.

Det Armata Pharmaceuticals P/E-forhold er -2,19.

Armata Pharmaceuticals KUV er 26,74.

AlleAktien Kvalitetsscore for Armata Pharmaceuticals er 7/10.

Den forventede Armata Pharmaceuticals omsætning er 3,14 mio. USD.

Den forventede Armata Pharmaceuticals indtjening er -38,38 mio. USD.

Armata Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of bacteriophage-based treatments for infections. The company is divided into two business segments: the antibody platform and the phage platform. The antibody platform focuses on the identification and development of monoclonal antibodies for the treatment of severe infectious diseases such as MRSA or Clostridium difficile. This platform utilizes the ability of antibodies to target specific structures on pathogenic bacteria. The goal is to develop safe and effective treatment options for patients whose infections cannot be treated with conventional antibiotics. The phage platform specializes in the research and development of bacteriophages. Bacteriophages are viruses that specialize in infecting and destroying bacteria. Armata's phage platform focuses on the identification and development of phages that target bacteria harmful to human health. The aim of the platform is to develop more effective and broadly applicable treatments for infections that are no longer responsive to conventional antibiotics. Armata is focused on researching treatments for bacterial infectious diseases, which are becoming increasingly common and can have serious consequences for patients' health. By using new and innovative technologies and developing products that counteract resistant bacterial strains, Armata's products are of great interest to the healthcare sector. Armata aims to provide innovative and life-saving drugs that help meet the growing demand for effective treatment options for infections. The company collaborates closely with scientists and other companies to leverage the latest developments in biotechnology and ensure that its products meet the highest quality standards. Armata has already launched several products on the market, including AR-301, a monoclonal antibody for the treatment of Staphylococcus aureus infections, and AP-SA01, a phage-based treatment for Staphylococcus aureus. The company is also working on the development of additional products to expand the range of therapeutic options. Overall, Armata Pharmaceuticals is a promising biotech company specializing in the development of treatments that aim to address the current need for effective treatments for infectious diseases. The company utilizes advanced technologies such as antibodies and phages to develop new and innovative product solutions that contribute to improving the well-being of patients worldwide.

Armata Pharmaceuticals udbetaler et udbytte på 0 USD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Armata Pharmaceuticals, eller selskabet udbetaler ikke udbytte.

ISIN'en for Armata Pharmaceuticals er US04216R1023.

WKN for Armata Pharmaceuticals er A2PKLC.

Tickeren for Armata Pharmaceuticals er ARMP.

I løbet af de sidste 12 måneder betalte Armata Pharmaceuticals en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Armata Pharmaceuticals sandsynligvis betale en dividende på 0 USD.

Udbytteafkastet for Armata Pharmaceuticals er i øjeblikket .

Armata Pharmaceuticals betaler kvartalsvis udbytte. Dette uddeles i månederne .

Armata Pharmaceuticals betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 USD. Dette svarer til et dividendeafkast på 0 %.

Armata Pharmaceuticals bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Armata Pharmaceuticals fra den 7.9.2024 på 0 USD, skulle du have haft aktien i din portefølje før ex-datoen den 7.9.2024.

Udbetalingen af det sidste udbytte blev foretaget den 7.9.2024.

I løbet af 2023 udbetalte Armata Pharmaceuticals 0 USD i form af dividender.

Udbytterne fra Armata Pharmaceuticals udbetales i USD.